StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
Huagongshe Open Project：[email protected]KI-Anbindung: llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.7.8
  1. Startseite
  2. /Verbindung

Talbutal

HCID 8275
NotizenReaktionen
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
115-44-6
Standard-SMILES
C=CCC1(C(C)CC)C(=O)NC(=O)NC1=O
InChIKey
BJVVMKUXKQHWJK-UHFFFAOYSA-N
Summenformel
C11H16N2O3
Durchschnittliche Molmasse
224,26 g/mol
Monoisotopische Masse
224,11609238

Überblick

Talbutal is a member of barbiturates.

Namen und Bezeichner

Bevorzugter Name
Talbutal
IUPAC
5-butan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
Englischer Name
TALBUTAL CIII (250 MG)
Summenformel
C11H16N2O3
Molmasse
224.26

Namen und Synonyme

TALBUTALLotusateProfundol115-44-65-Allyl-5-sec-butylbarbituric acidTalbutaleTalbutalumsec-Butyl allyl barbituric acidWIN 5095DTXSID8023630Barbituric acid, 5-allyl-5-sec-butyl-4YIR8202AX
Weitere Namen anzeigen
LatusateTALBUTAL CIII (250 MG)sec-butylallylbarbituricacid5-isobutyl-5-allylbarbituricacid5-allyl-5-sec-butyl-barbituricaci5-allyl-5-sec-butylbarbituricacid
2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylpropyl)-5-(2-propenyl)-DTXCID4036305-(butan-2-yl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trioneRefChem:56087allyl-sec-butyl-barbituric acidN05CA07204-090-4Talbutal [INN]

Datenbank-Bezeichner

CAS
115-44-6
PubChem CID
8275
DTXSID
DTXSID8023630
ChEMBL
CHEMBL1200802
ChEBI
CHEBI:134923

Eigenschaften

Berechnete Struktureigenschaften

XLogP
1,4
Polarare Oberfläche (TPSA)
75,3 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
4
Schwere Atome
16
Formalladung
0
Komplexität
329

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

DEA NFLIS-Drug Category -> Depressants and Tranquilizers

Pharmaceuticals -> Barbiturates

pHSATURATED AQ SOLN IS ACID TO LITMUS
LogP1.47
OdorMAY HAVE SLIGHT ODOR OF CARAMEL
TasteSLIGHTLY BITTER TASTE
Color/Form · 2 Einträge

CRYSTALS FROM WATER OR DIL ALCOHOL

WHITE, CRYSTALLINE POWDER

SolubilityPRACTICALLY INSOL IN WATER & PETROLEUM ETHER SOL IN ALCOHOL, CHLOROFORM, ETHER, ACETONE, GLACIAL ACETIC ACID, FIXED ALKALI HYDROXIDE SOLN
Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point108-110 °C
Dissociation Constants · 2 Einträge

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Gefahrenhinweise

FDA Requirements · 5 Einträge

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

5-Allyl-5-sec-butylbarbituric acid is a chemical derivative of barbituric acid, named in section 502(d) of the Federal Food, Drug, and Cosmetic Act, and is hereby designated as habit forming.

Warning and caution statements for 5-allyl-5-sec-butylbarbituric acid specifically required by law. PREPARATIONS CONTAINING HABIT-FORMING DERIVATIVES OF SUBSTANCES NAMED IN SECTION 502(d) OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT ... The statement "Warning-May be habit forming" is required to appear on the labels of all drugs containing derivatives designated in 21 CFR 329.1 ... as habit forming.

Schedules of controlled substances are established by section 202 of the Controlled Substances Act (21 U.S.C. 812). Schedule III includes any substance which contains any quantity of a derivative of barbituric acid or any salt thereof. DEA Code #2100; Drug class: Depressant. /Derivatives of barbituric acid or any salt thereof/

For more FDA Requirements (Complete) data for TALBUTAL (7 total), please visit the HSDB record page.

Hazard Classes and CategoriesAcute Tox. 3 (100%)

Sicherheit und Schutzausrüstung

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

N - Nervous system

QN - Nervous system

Pharmacodynamics · 1 Eintrag

Talbutal is a short to intermediate-acting barbiturate that is a nonselective central nervous system (CNS) depressant. As with other barbiturates, talbutal is capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. Barbiturates may also induce anesthesia at sufficiently high therapeutic doses.

Mechanism of Action · 6 Einträge

Talbutal binds to GABA<sub>A</sub> receptors at a distinct binding site associated with a Cl<sup>-</sup> ionopore of the receptor. Upon binding, talbutal increases the duration of time for which the Cl<sup>-</sup> ionopore is open, leading to prolonged inhibitory effect of GABA at the postsynaptic thalamic neuron.

BARBITURATES REVERSIBLY DEPRESS ACTIVITY OF ALL EXCITABLE TISSUES. NOT ALL TISSUES ARE AFFECTED @ SAME DOSE OR CONCN; CNS IS EXQUISITELY SENSITIVE, SO THAT WHEN BARBITURATES ARE GIVEN IN SEDATIVE OR HYPNOTIC DOSES, VERY LITTLE EFFECT ON SKELETAL, CARDIAC, OR SMOOTH MUSCLE OCCURS. /BARBITURATES/

... RETICULAR ACTIVATING SYSTEM IS EXQUISITELY SENSITIVE TO DEPRESSANT EFFECTS OF BARBITURATES ... WHATEVER ... EFFECTS OF BARBITURATES ELSEWHERE IN CNS, IT IS EFFECT ON RETICULAR SYSTEM THAT SEEMS TO BE RESPONSIBLE FOR INABILITY TO MAINTAIN WAKEFULNESS UNDER INFLUENCE OF BARBITURATE. /BARBITURATES/

BARBITURATES ARE RESP DEPRESSANTS, AFFECTING BOTH DRIVE TO RESP & MECHANISM RESPONSIBLE FOR RHYTHMIC CHARACTER OF RESP MOVEMENT. /BARBITURATES/

The mechanism(s) of action of the barbiturates is not completely known. Although the drugs act throughout the CNS, a site of particular sensitivity is the polysynaptic midbrain reticular formation which is concerned with the arousal mechanism. Barbiturates induce an imbalance in central inhibitory and facilitatory mechanisms influencing the cerebral cortex and the reticualar formation. The significance of the effect of barbiturates on neurotransmitters is unclear. It appears that the drugs decrease the excitability of both presynaptic and postsynaptic membranes. It has not been determined which of the various actions of barbiturates at cellular and synaptic levels are responsible for their sedative and hypnotic effects. /Barbiturates/

For more Mechanism of Action (Complete) data for TALBUTAL (9 total), please visit the HSDB record page.

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen

Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.

Notizen zur Verbindung

Wird geladen…

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
UNII
4YIR8202AX
EC Number
204-090-4
Nikkaji
J47.150J

7.79 (at 25 °C)

PKA: ABOUT 9.4

Other Experimental PropertiesMAY OCCUR IN POLYMORPHIC FORM THAT MELTS @ ABOUT 111 °C

Physikochemische Eigenschaften

Schmelzpunkt
108 · 108-110°
Siedepunkt
365.66 °C · 365.66°C (rough estimate)
Dichte
1.1672 · 1.1672 (rough estimate)
Brechungsindex
1.5 · 1.5000 (estimate)
Löslichkeit
Chloroform (Slightly, Heated), Methanol (Slightly, Heated)
Aggregatzustand
Solid
Farbe
White to Off-White
Wasserlöslichkeit
2.16 g/L · 2.16g/L(temperature not stated)
EPA chemische Informationen
2 · 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylpropyl)-5-(2-propen-1-yl)- (115-44-6)
Storage ConditionsStore below 40 °C (104 °F), preferably between 15 and 30 °C. ... Store in a tight container.

Toxikologische Informationen

Body BurdenBarbiturates are distributed into the milk of nursing women. /Barbiturates/
Interactions · 5 Einträge

... BARBITURATES MAY CAUSE DECR HYPOPROTHROMBINEMIC EFFECT OF ORAL ANTICOAGULANTS. ... BARBITURATES INTERACT WITH ADRENAL CORTICOSTEROIDS TO CAUSE REDUCED SERUM LEVELS & DECR SYSTEMIC EFFECTS OF STEROIDS; PROBABLE MECHANISM IS INDUCTION OF MICROSOMAL ACTIVITY. /BARBITURATES/

DECR SERUM LEVELS OF DOXYCYCLINE (VIBRAMYCIN) ... REPORTED WHEN BARBITURATE ... GIVEN CONCURRENTLY; PROBABLE MECHANISM IS INDUCTION OF MICROSOMAL ENZYME ACTIVITY. DECR SERUM LEVELS OF GRISEOFULVIN ... NOTED ... CHLORPROMAZINE MAY BE MORE RAPIDLY METABOLIZED WHEN BARBITURATES ... GIVEN CONCURRENTLY. /BARBITURATES/

MONOAMINE OXIDASE INHIBITORS POTENTIATE ACTION OF BARBITURATES ... /BARBITURATES/

LETHAL BLOOD ... /LEVEL/ ... MAY BE ... 1 MG/100 ML FOR INTERMEDIATE- & SHORT-ACTING BARBITURATES; IF OTHER DEPRESSANT DRUGS OR ALC ARE ALSO PRESENT, LETHAL CONCN MAY BE EVEN LOWER. /BARBITURATES, SHORT & INTERMEDIATE ACTING/

For more Interactions (Complete) data for TALBUTAL (16 total), please visit the HSDB record page.

Milk ConcentrationsBarbiturates are distributed into the milk of nursing women. /Barbiturates/
Human Toxicity Excerpts · 5 Einträge

SEVERE OLIGURIA OR ANURIA MAY OCCUR IN ACUTE ... POISONING, LARGELY AS RESULT OF MARKED HYPOTENSION. /BARBITURATES/

BARBITURATES COMBINE WITH CYTOCHROME P-450 & ... COMPETITIVELY INTERFERE WITH BIOTRANSFORMATIONS OF ... /ITS/ SUBSTRATES. /BARBITURATES/

SHORT-ACTING BARBITURATES ARE MORE POTENT &, OF COURSE, MORE TOXIC THAN LONG-ACTING COMPD. /BARBITURATES, SHORT-ACTING/

May be habit forming.

For more Human Toxicity Excerpts (Complete) data for TALBUTAL (13 total), please visit the HSDB record page.

Non-Human Toxicity Excerpts · 1 Eintrag

IN ACUTE BARBITURATE POISONING RESPIRATION BECOMES SHALLOW & LOW &, WHEN INTOXICATION IS FULLY DEVELOPED, THERE IS EXTREME LETHARGY & COMA, WITH DISAPPEARANCE OF REFLEXES; PUPILS BECOME DILATED. DEATH OCCURS FROM RESP FAILURE, DUE TO DEPRESSION OF RESPIRATORY CENTER. /BARBITURATES/

Antidote and Emergency Treatment · 4 Einträge

TREATMENT: Stabilization: Respiratory arrest is the major cause of early death. Assess the patency of the airway and the adequacy of ventilation first. Appropriate corrective measures include supplemental oxygen, head tilt-chin lift, intubation, and assisted ventilation. Establish an iv line with Ringer's lactate and give a fluid challenge up to 2 l for patients who are hypotensive. Cardiac dysrhythmias are rare but were reported. ... Be sure to give glucose, naloxone, and thiamine to all patients with depressed mental status. /Barbiturates/

Gut Decontamination: Because of decr gastrointestinal mobility and delayed gastric emptying, gut decontamination is indicated 6-8 hr postingestion in obtunded patients. Barbiturates are well absorbed by charcoal; 10 times the ingested dose (or 1 g/kg body weight) should be given together with a cathartic (sorbitol, magnesium citrate) to all patients. /Barbiturates/

Elimination Enhancement: Most overdose patients respond to supportive care and require no special measures. ... Alkaline diuresis is ineffective for short and intermediate acting barbiturates. ... Hemoperfusion: This measure is more effective than dialysis for short and intermediate acting barbiturates. ...

Antidotes: No effective antidotes are available. Respiratory and central nervous stimulants incr complications and should be avoided. /Barbiturates/

Regulatorische Informationen

FDA Requirements · 5 Einträge

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

5-Allyl-5-sec-butylbarbituric acid is a chemical derivative of barbituric acid, named in section 502(d) of the Federal Food, Drug, and Cosmetic Act, and is hereby designated as habit forming.

Warning and caution statements for 5-allyl-5-sec-butylbarbituric acid specifically required by law. PREPARATIONS CONTAINING HABIT-FORMING DERIVATIVES OF SUBSTANCES NAMED IN SECTION 502(d) OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT ... The statement "Warning-May be habit forming" is required to appear on the labels of all drugs containing derivatives designated in 21 CFR 329.1 ... as habit forming.

Schedules of controlled substances are established by section 202 of the Controlled Substances Act (21 U.S.C. 812). Schedule III includes any substance which contains any quantity of a derivative of barbituric acid or any salt thereof. DEA Code #2100; Drug class: Depressant. /Derivatives of barbituric acid or any salt thereof/

For more FDA Requirements (Complete) data for TALBUTAL (7 total), please visit the HSDB record page.

Sicherheitsdaten

ridadr
3249
Toxizität
LD50 orally in rats: 57.5 mg/kg (Schafer)
hazard_class
6.1(b)
packing_group
III
Giftige Stoffe Daten
115-44-6(Hazardous Substances Data)
Biological Half-LifeHalf-life 15 hr
Metabolism/Metabolites · 3 Einträge

MOST BARBITURATES ARE TRANSFORMED IN BODY TO INACTIVE METABOLITES. PRINCIPAL SITE OF BIOTRANSFORMATION IS LIVER. OXYBARBITURATES ARE TRANSFORMED ONLY BY LIVER; THIOBARBITURATES MAY BE TRANSFORMED TO SMALL EXTENT IN OTHER TISSUES, ESP KIDNEY & BRAIN ... /BARBITURATES/

Hepatic biotransformation, primarily by the hepatic microsomal enzyme system. /Barbiturates/

With the exception of the less lipid-soluble aprobarbital and phenobarbital, nearly complete metabolism and/or conjugation of barbiturates in the liver precedes their renal excretion. The oxidation of radicals at C5 is the most important biotransformation responsible for termination of biological activity. Oxidation results in the formation of alcohols, kentones, phenols, or carboxylic acids, which may appear in the urine as such or as glucuronic acid conjugates. In some instances (e.g., phenobarbital), N-glucosylation is an important metabolic pathway. Other biotransformations include N-hydroxylation, desulfuration of thiobarbiturates to oxybarbiturates, opening of the barbituric acid ring, and N-dealkylation of N-alkylbarbiturates to active metabolites (e.g., mephobarbital to phenobarbital).

Absorption, Distribution and Excretion · 5 Einträge

THERE EXISTS NO IMPENETRABLE BARRIER TO DIFFUSION OF BARBITURATES IN BODY ... SMALL AMT ... MAY APPEAR IN MILK AFTER INGESTION OF LARGE DOSES. ... READILY CROSS PLACENTAL BARRIER, &, WITHIN FEW MIN AFTER INJECTION OF SHORT-... ACTING BARBITURATE, CONCN IN FETAL BLOOD APPROACHES THAT IN MATERNAL VENOUS BLOOD. /BARBITURATES/

THREE MOST IMPORTANT FACTORS AFFECTING DISTRIBUTION & FATE OF BARBITURATES ARE LIPID SOLUBILITY ... PROTEIN BINDING, & EXTENT OF IONIZATION. ... THE MORE HIGHLY LIPID-SOL COMPD ARE SHORT-ACTING AGENTS... THEY TEND TO BE MORE RAPIDLY DEGRADED METABOLICALLY & ARE ALMOST COMPLETELY REABSORBED BY RENAL TUBULE. /BARBITURATES/

For sedative hypnotic use, the barbiturates are usually administered orally. Such doses are rapidly and probably completely absorbed; sodium salts are absorbed more rapidly than the corresponding free acids, especially from liquid formulations. The onset of action varies from 10 to 60 min, depending upon the agent and the formulation, and is delayed by the presence of food in stomach. /Barbiturates/

Barbiturates are distributed widely and readily cross the placenta. Binding to plasma proteins is a function of lipid solubility and is greatest for thiopental, which is bound to the extent of 65% or more. The highly lipid soluble barbiturates, led by those used to induce anesthesia, undergo redistribution after intravenous injection. Uptake into less vascular tissue, especially muscle and fat, leads to a decline in the concentration of barbiturate in the plasma and brain.

Elimination/% excreted unchanged: renal/trace

Verwendung und Herstellung

UsesMEDICATION
Methods of ManufacturingBY GENERAL METHOD DESCRIBED ... /FOR BARBITAL/ USING ALLYL BROMIDE & SEC-BUTYL BROMIDE AS ALKYLATING AGENTS.
Formulations/Preparations · 2 Einträge

LOTUSATE (WINTHROP). DOSAGE FORMS--TABLETS NF (TABLET IN CAPSULE FORM): 30, 50, & 120 MG.

Lotusate Caplets, oral caplets with talbutal 120 mg, lactose, magnesium stearate, starch, talc.

Anwendungen

VerwendenA stuctural isomer of Butalbital (B690100). A short to intermediate-acting barbiturate that act as nonselective depressants of the central nervous system (CNS). Sedative, hypnotic. Controlled Substance.

Anbieter7 Anbieter

凯试(上海)科技有限公司021-50135380 · [email protected]
MedChemexpress LLC021-58955995 · [email protected]
武汉丰泰威远科技有限公司027-87465837 19945049750 · [email protected]
陕西缔都医药化工有限公司029-81024372 17792795018 · [email protected]
HANGZHOU LEAP CHEM CO., LTD.+86-571-87711850 +86-15355479329 · [email protected]
艾吉析科技（上海）有限公司17717235263 17717235263 · [email protected]
Shaanxi Didu New Materials Co. Ltd+86-86-17392712779 +86-13289823923 · [email protected]